![April 5- 10, 2024, AACR Conference](https://aurigene-com.b-cdn.net/wp-content/uploads/2024/05/tumor-dividing-m-1-1.png)
April 5- 10, 2024, AACR Conference
1) SMARCA 2/4 Degraders Relieve The Differentiation Block In AML via Changes In Chromatin Looping and Accessibility2) Paralogue Selectivity p300 Degraders Induce Synthetic Lethality in Pre-Clinical Models of CBP- Deficient![April 1- 4, 2024, Drug Discovery Chemistry](https://aurigene-com.b-cdn.net/wp-content/uploads/2022/11/2-1.jpg)
April 1- 4, 2024, Drug Discovery Chemistry
1) A Highly Differentiated Small Molecule Immune Checkpoint Inhibitor Dually Targeting PD-L1 And A2AR for Cancer Therapy2) Targeting CBM, A Tri Protein Signalling Hub, by Inhibition Of MALT1 for theOctober 11-15, 2023, AACR- NCI- EORCT International Conference On Molecular Targets And Cancer Therapeutics
1) Identification of Paralogue Selective Degraders Of SMARCA2 And SMARCA4 for the Treatment of Various Cancers2) Discovery of Potent and Paralogue Selective PROTAC Degraders of CBP or P300 Proteins forSeptember 26-28, 2023, Discovery On Target
1) Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion and Therapeutic Resistance2) Targeting CBP/P300 – Inhibition vs. Degradation for Potent Anti-Tumor EfficacyJune 8-11, 2023, European Hematology Association
1) A Phase 1, Open Label, Dose Escalation, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR-103 in Patients with Relapsed Advanced Malignancies (BHARAT-1)April 14 – 19, 2023, AACR
1) Generation of Profound Anti-Tumor Immunity by AUR-109, A Spectrum-Selective Tyrosine Kinase Inhibitor, Either as a Single Agent or in Combination with Immune Checkpoint Inhibitors2) A Highly Differentiated A2AR InhibitorApril 10-13, 2023, Drug Discovery Chemistry
1) Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy![May 10 – 12, 2022, Adenosine-Pathway Targeted Cancer Immunotherapy Summit](https://aurigene-com.b-cdn.net/wp-content/uploads/2022/11/know-img1.png)
May 10 – 12, 2022, Adenosine-Pathway Targeted Cancer Immunotherapy Summit
Dual Targeting of CD73 & A2AR for Effective Suppression of Adenosine Signaling May 11 2022![April 18-22, 2022, Drug Discovery Chemistry](https://aurigene-com.b-cdn.net/wp-content/uploads/2022/04/Drug-Discovery-Chemistry.jpg)